From Cure Today:
Opdivo (nivolumab) improved both survival and quality of life for patients with advanced renal cell carcinoma (RCC) and is changing the way the disease is treated. The potential for the PD-1 inhibitor, which was approved by the FDA in advanced RCC based on findings from the CheckMate-025 trial in November 2015, has only continued to grow since it first hit the market. A recent analysis, which looked at long-term data from phase 1 and phase 2 clinical trials of single-agent Opdivo in RCC, found that one-third of patients were still alive at four and five years. In addition, responses were shown to be consistent across patient subgroups.
